


Supplementary Figure S2. Time on treatment by taselesib dose and duration



AE, adverse event; MND, mutation not detected; MUT, *PIK3CA*-mutated; PD, progressive disease; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit- α ; PR, partial response; UNK, unknown *PIK3CA* mutation status; >>> indicates treatment ongoing at time of data cutoff.